← board
JSPRW
distress 8/10 · high distress / dilution risk$0.02+55%today0% from 52w high
Revenue
pre-revenue
Liquidity
$18M
Runway
0.3 yrs
Shares 1y
+72%
Price & events
+7.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+54.5%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
—
6M
—
1Y
—
2Y
—
5Y
+7.9%
All
Overview
- Market Cap
- $571.13K
- Volume
- 0
- 52 Week Range
- $0.01 – $0.02
- Total Shares
- 28.00M
- Float Shares
- 23.31M
- Beta
- 3.07
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-06-25Jasper Therapeutics Inc (JSPRW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
- 2026-06-18Jasper Therapeutics Inc (JSPRW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
- 2026-06-18Jasper Therapeutics Inc (JSPRW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
- 2026-06-17Jasper Therapeutics Inc (JSPRW) Valuation: PE, PB & Fair Value Analysis - TradingKey
- 2026-06-09Nasdaq warns Jasper Therapeutics (JSPR) on sub-$1 bid, delisting risk noted - Stock Titan
- 2026-06-01Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1 – Minichart - Minichart
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.